Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with hair growth stimulants (minoxidil) (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone) +… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with contact immunotherapy (diphencyprone) (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Topical hair growth stimulants (minoxidil) changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Other therapies (cryotherapy) changes short‐term hair regrowth ≥ 75% compared with other therapies (fractional CO2 laser) (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema
Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8) · adults with eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Twice daily or more showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with once daily topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Twice daily or more showed no clear difference in patient‐reported symptoms of eczema: PGA (number with cleared or… compared with once daily topical corticosteroid (low certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema
Potent probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Investigator Global Assessment · atopic eczema
Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · atopic eczema
1 finding from 1 review
Physician‐assessed changes in clinical signs · atopic eczema
1 finding from 1 review